Oncogene mutations in colorectal polyps identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) screening study

12Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Data are limited on oncogene mutation frequencies in polyps from principally asymptomatic participants of population-based colorectal cancer screening studies. In this study, DNA from 204 polyps, 5 mm or larger, were collected from 176 participants of the NORCCAP screening study and analyzed for mutations in KRAS, BRAF, and PIK3CA including the rarely studied KRAS exons 3 and 4 mutations. KRAS mutations were identified in 23.0% of the lesions and were significantly associated with tubulovillous adenomas and large size. A significantly higher frequency of KRAS mutations in females was associated with mutations in codon 12. The KRAS exon 3 and 4 mutations constituted 23.4% of the KRAS positive lesions, which is a larger proportion compared to previous observations in colorectal cancer. BRAF mutations were identified in 11.3% and were associated with serrated polyps. None of the individuals were diagnosed with de novo or recurrent colorectal cancer during the follow-up time (median 11.2 years). Revealing differences in mutation-spectra according to gender and stages in tumorigenesis might be important for optimal use of oncogenes as therapeutic targets and biomarkers.

Cite

CITATION STYLE

APA

Lorentzen, J. A., Grzyb, K., De Angelis, P. M., Hoff, G., Eide, T. J., & Andresen, P. A. (2016). Oncogene mutations in colorectal polyps identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) screening study. Clinical Medicine Insights: Pathology, 9(1), 19–28. https://doi.org/10.4137/CPath.s40143

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free